國家衛生研究院 NHRI:Items for Author

Year

Loading year class tree, please wait....

Items for Author "Bai, LY"

Return to Browse by Author

Showing 40 items.

Collection	Date	Title	Relation
[陳立宗] 期刊論文	2024-08-20	Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri	-
[陳立宗] 期刊論文	2024-08-06	Pan-Asian adapted ESMO clinical practice guidelines for the diagnosis, treatment and follow-up of patients with biliary tract cancer	-
[蔡慧珍] 期刊論文	2024-07-11	Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: A nationwide registry study	-
[蘇勇曄] 期刊論文	2024-06	Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation	-
[陳立宗] 期刊論文	2024-05	Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer	-
[其他] 期刊論文	2024-01	Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study	-
[陳立宗] 期刊論文	2023-08	The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study	-
[姜乃榕] 會議論文/會議摘要	2023-06	Phase 1 studies of D07001-F4 and D07001-softgel capsule: Oral metronomic gemcitabine in subjects with advanced solid tumors	-
[陳立宗] 期刊論文	2023-02-05	Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer	-
[蘇勇曄] 期刊論文	2022-11-15	The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma	-
[蕭金福] 會議論文/會議摘要	2022-11	BEAR study: A single-arm, phase II trial of BI-754091 and afatinib for refractory esophageal squamous cell carcinoma	-
[陳立宗] 期刊論文	2022-10	Impaired chromatin remodeling predicts better survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract Cancer: A phase II T1219 study	-
[姜乃榕] 期刊論文	2022-09-15	Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin	-
[姜乃榕] 期刊論文	2022-09	A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study	-
[陳立宗] 會議論文/會議摘要	2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	-
[陳立宗] 期刊論文	2022-06-22	Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study	-
[姜乃榕] 期刊論文	2022-06	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin	-
[姜乃榕] 期刊論文	2022-04-15	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan	-
[陳立宗] 會議論文/會議摘要	2022-02-01	A prospective phase II study of biweekly S-1, leucovorin and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma	-
[陳立宗] 期刊論文	2022-02	Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial	-
[姜乃榕] 會議論文/會議摘要	2022-02	Phase 1 study of nanoliposomal irinotecan in combination with trifluridine/tipiracil in refractory solid tumors	-
[陳立宗] 期刊論文	2022-01	Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: Post hoc subanalysis from the ATTRACTION-2 study	-
[楊奕馨] 期刊論文	2021-11-30	Survival outcomes of management in metastatic gastric adenocarcinoma patients	-
[蘇勇曄] 期刊論文	2021-11-20	Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study	-
[陳立宗] 期刊論文	2021-10	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: A randomised, double-blind, multicentre, phase 2 study	-
[姜乃榕] 會議論文/會議摘要	2021-09	A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer	-
[陳立宗] 期刊論文	2021-07	Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab	-
[黃秀芬] 期刊論文	2021-07	Exploring markers of exhausted CD8 T cells to predict response to immune checkpoint inhibitor therapy for hepatocellular carcinoma	-
[姜乃榕] 會議論文/會議摘要	2021-05	TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma	-
[姜乃榕] 會議論文/會議摘要	2021-05	A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy	-
[陳立宗] 期刊論文	2020-12-29	Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan	-
[陳立宗] 會議論文/會議摘要	2020-09	Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study	-
[陳立宗] 期刊論文	2020-05	A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data	-
[陳立宗] 會議論文/會議摘要	2020-02	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study	-
[陳立宗] 期刊論文	2020-01	Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: A randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer	-
[陳立宗] 期刊論文	2019-10	A randomized controlled, open label, adaptive phase III Trial to evaluate safety and efficacy of endoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FO	-
[陳立宗] 期刊論文	2017-12	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial	-
[姜乃榕] 會議論文/會議摘要	2016-02	Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy	-
[陳立宗] 期刊論文	2015-05	A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer	-
[潘秀玲(2009-2013)] 期刊論文	2011-12	Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma	-

Loading...

Category

Year

Items for Author "Bai, LY"